Prestige Consumer Healthcare Inc
NYSE:PBH
Prestige Consumer Healthcare Inc
NYSE:PBH
Price:
71.26 USD
0.2%
Updated:
May 3, 2024
EV/EBITDA
Enterprise Value to EBITDA
Enterprise Value to EBITDA
468.6
Current
12.5
Median
13.6
Industry
Higher
than median
Higher
than industry value
Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.
EV/EBITDA
=468.6
Enterprise Value
/
4.7B
EBITDA
10m
All Countries
| Market Cap | EV/EBITDA | ||||
|---|---|---|---|---|---|
| US |
|
Prestige Consumer Healthcare Inc
NYSE:PBH
|
3.5B USD | 468.6 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | -5 459 134.4 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
717.6B USD | 61.8 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
3.7T DKK | 32.7 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 3 846.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
360.9B USD | 11.9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
324.7B USD | 33.5 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
187.8B GBP | 140.7 | |
| CH |
|
Novartis AG
SIX:NOVN
|
181.2B CHF | 9.8 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
172.7B CHF | 8.6 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
156.4B USD | 11 |
EV/EBITDA Forward Multiples
Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
EV/EBITDA
12.1
2-Years Forward
EV/EBITDA
11.8
3-Years Forward
EV/EBITDA
11.5
You don't have any saved screeners yet
